2.2. Inhibitory Effect of Anti-IL-6R Antibody Treatment (Tocilizumab; ACTEMRA®) on the Tumor Growth of Human CRC SW480 Xenografts Was Superior to the Treated Group of HT-29 Xenografts. The gene discussed is IL6R; the disease is neoplasm.